Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Receivables (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Receivables data on record, last reported at $233.9 million in Q3 2025.

  • For Q3 2025, Receivables rose 2.4% year-over-year to $233.9 million; the TTM value through Sep 2025 reached $233.9 million, up 2.4%, while the annual FY2024 figure was $253.5 million, 41.23% up from the prior year.
  • Receivables reached $233.9 million in Q3 2025 per COLL's latest filing, up from $213.0 million in the prior quarter.
  • Across five years, Receivables topped out at $253.5 million in Q4 2024 and bottomed at $90.1 million in Q2 2021.
  • Average Receivables over 5 years is $179.2 million, with a median of $181.9 million recorded in 2023.
  • Peak YoY movement for Receivables: surged 119.21% in 2022, then dropped 15.2% in 2023.
  • A 5-year view of Receivables shows it stood at $105.8 million in 2021, then surged by 73.01% to $183.1 million in 2022, then decreased by 1.96% to $179.5 million in 2023, then surged by 41.23% to $253.5 million in 2024, then dropped by 7.73% to $233.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $233.9 million in Q3 2025, $213.0 million in Q2 2025, and $228.7 million in Q1 2025.